Reference

Last reviewed: 28 Apr 2026
Sources cited: 9
Residues: 4

Primary structure4 residues · 390.4 Da

01AlaAlanine

02GluGlutamate

03AspAspartate

04GlyGlycine

Nonpolar Polar Acidic Basic Aromatic Gly/Pro

Epithalon

Last verified: 2026-04-24

At a glance


Also known as	Epitalon, Epithalone, AEDG, Ala-Glu-Asp-Gly
Class	Synthetic tetrapeptide, pineal bioregulator
Typical route	Subcutaneous injection; intranasal increasingly common
Plasma half-life	Not established. Significant knowledge gap.
Duration of effect	Biological effects (melatonin, telomerase expression, gene regulation) persist days to weeks after short cycles; plasma profile unknown
Molecular weight	390.4 Da
Sequence	Ala-Glu-Asp-Gly (4 amino acids — the shortest peptide in this encyclopedia)

What it is

Epithalon is a synthetic tetrapeptide derived from epithalamin, a bovine pineal gland extract. It was developed in the 1980s by Vladimir Khavinson and colleagues at what became the St. Petersburg Institute of Bioregulation and Gerontology. The synthetic version (AEDG) is a simplified four-amino-acid analogue of the active components of the natural pineal extract.

It sits at the intersection of longevity research and biohacker interest, marketed primarily as an anti-ageing peptide that activates telomerase, restores age-related melatonin decline, and normalises circadian rhythms. The claims are provocative; the evidence is almost entirely from a single Russian research group over four decades, with one meaningful independent Western replication in 2025 that both validated the telomerase claim and raised a substantive cancer concern (see Areas of concern).

Epithalon is among the most-hyped peptides in the longevity space and among the least-rigorously-studied. Users often report notable sleep improvement after short cycles. Whether that — or the telomerase effect, or the longevity benefit — translates into meaningful lifespan or healthspan extension in healthy humans is unresolved.

Mechanism

Epithalon’s proposed mechanisms are multiple and only partially characterised:

Telomerase activation. The best-known mechanism. Epithalon upregulates hTERT (the catalytic subunit of telomerase), increasing telomerase activity and extending telomere length. Demonstrated in multiple human cell lines in vitro, including a 2025 Brunel University independent replication.1
Alternative Lengthening of Telomeres (ALT) activation. The 2025 study found Epithalon activates ALT in cancer cell lines — a mechanism many cancers use to achieve replicative immortality.1 This is significant and poorly reflected in biohacker content.
Melatonin synthesis restoration. Epithalon upregulates AANAT (the rate-limiting enzyme in melatonin synthesis) and pCREB in pinealocytes. Restores age-related decline in melatonin output in aged monkeys and humans.
Circadian rhythm entrainment. Shown to re-entrain circadian clock genes and restore cortisol rhythm in aged primates.
Pineal tissue protection. Direct protective effect on aged pinealocytes against degenerative changes.
Immune modulation. Alters IL-2 mRNA expression and modulates thymocyte mitogenic activity.
Enzyme regulation. Enhances activity of acetylcholinesterase, butyrylcholinesterase, and other enzymes — implicating effects on cholinergic signalling and neurodegenerative-disease-relevant pathways.

The peptide is endogenous — it was detected in physiological human pineal extracts in 2017, confirming it exists naturally in the body, not just as a synthetic compound.

Routes of administration

Subcutaneous injection


Bioavailability	Not formally quantified; assumed standard subQ efficiency
Onset	Biological (gene expression) changes detectable within 24 hours; subjective effects over days
Duration	Effects persist for weeks after short cycles
Typical dose (this route)	5–10 mg/day
Equipment	Insulin syringe, BAC water, alcohol wipes
When this route makes sense	Evidence-aligned route. Most Russian clinical and preclinical studies used injection.

The evidence-aligned default. Almost all Khavinson-group research and the Western replication study used injection (SC, IM, or IV depending on context). Community doses are usually 5–10 mg/day for 10–20 consecutive days.

Intramuscular injection


Bioavailability	Similar to SC for peptide distribution
Onset	Slightly slower than SC; in one study IL-2 mRNA effect took 24h vs 1.5h for nasal
Typical dose (this route)	5–10 mg/day (same as SC)
When this route makes sense	Used in some Russian clinical studies. Community preference is SC.

Essentially interchangeable with SC for community purposes. No meaningful clinical advantage.

Intranasal


Bioavailability	Estimated 5–15% vs injection — significantly lower than injected routes
Onset	Fast CNS effects (IL-2 mRNA in hypothalamus within 1.5h vs 24h for IM)
Duration	Similar biological window
Typical dose (this route)	2–5 mg/day (higher doses sometimes used to compensate for lower bioavailability)
Equipment	0.1% or higher-concentration nasal solution
When this route makes sense	Needle-averse users, convenience, specific CNS-targeted use-cases

Important caveat: intranasal Epithalon has faster CNS onset for brain-targeted effects (like melatonin/circadian modulation) but significantly lower systemic bioavailability. Users dosing intranasally for telomere/longevity effects may not be reaching effective systemic concentrations at standard doses — this is under-discussed in the community. If your primary interest is sleep and circadian effects, intranasal is reasonable. If your primary interest is telomere extension and systemic longevity effects, injection is probably necessary.

Oral / sublingual


Bioavailability	Likely negligible. No formal characterisation.
Typical dose (this route)	Not recommended
When this route makes sense	Rarely. Some sublingual products exist but evidence is absent.

Cross-route comparison

For longevity/telomere effects → injection (SC most commonly). This is the route the research used.

For sleep/circadian effects → intranasal is reasonable and possibly faster-onset, at the cost of needing to accept that systemic effects are muted.

The community mistake is assuming intranasal Epithalon at standard doses achieves the effects documented in injection studies. It probably doesn’t — the bioavailability difference is an order of magnitude.

What the evidence says

Honest summary: long research history, almost entirely from one Russian research group, one meaningful independent Western replication in 2025 that confirmed the telomerase mechanism and raised a cancer concern.

Khavinson group (Russia, 1980s–present):

Decades of animal work across rats, mice, and rhesus monkeys. Consistent findings: modest lifespan extension, reduced tumour incidence in some tumour-prone strains, restored melatonin rhythms in aged primates, circadian gene expression normalisation.
Human studies including two of the most-cited: patients aged 60–65 and 75–80 with measured telomere length increases in blood cells after Epithalon/Epithalamin courses.2
Retinitis pigmentosa trial — 90% positive clinical effect reported.
Pulmonary tuberculosis trial — did not correct existing chromosomal aberrations but protected against development of new ones.
Important caveat: virtually every study cited in Epithalon literature from 1980–2020 comes from this single research group. No independent replication by any Western academic institution during this period.

2025 Brunel University independent replication:

The single most important recent Epithalon paper. First meaningful independent Western work on the compound.1
Tested two breast cancer lines (21NT, BT474) and two normal cell types (IBR.3 fibroblasts, HMEC epithelial cells). Cancer cells: 0.1–1.0 μg/mL for 4 days. Normal cells: 1.0 μg/mL for 3 weeks.
Confirmed telomere length extension across all cell types. Normal cells showed 4–26-fold increases in telomerase activity.
Critical finding: In cancer cells, despite 12-fold increases in hTERT expression, telomerase activity did not significantly increase. Instead, cancer cells showed a ten-fold increase in ALT (Alternative Lengthening of Telomeres) activity — the mechanism many cancers use to achieve replicative immortality.
The authors position this as independent quantification and validation of Khavinson’s foundational work rather than new discovery. They acknowledge the 2D cell-culture limitation and call for 3D and animal studies.
What this means: the telomerase mechanism is real, but the cancer cell behaviour (ALT activation) is new information that should reshape how the cancer risk is discussed.

Regulatory reality:

Epithalon has never been approved as a pharmaceutical in any jurisdiction, including Russia.
Epithalamin (the pineal extract from which Epithalon was derived) is approved in Russia for menopause-related symptoms, anovulatory infertility, and hormone-dependent tumours. This is a different compound — the bovine extract, not the synthetic tetrapeptide.
This distinction matters. “Approved in Russia” claims often conflate Epithalamin (approved) with Epithalon (not approved).

Community evidence:

Sleep improvement is the most consistently reported subjective effect. Users describe deeper sleep, more vivid dreams, waking more rested, often within the first 3–5 days of a cycle. This is consistent with the melatonin-synthesis mechanism.
Longevity and anti-ageing effects are by definition not perceptible on human timescales — users report these based on markers (perceived skin quality, energy levels, cognition) rather than measured outcomes.
Non-response is less common than with Semax or DSIP; most users report at least the sleep effect.

Typical use patterns

Observations, not recommendations.

Dose:

Russian clinical standard: 5–10 mg/day
Community standard (injection): 5–10 mg/day
Community standard (intranasal): 2–5 mg/day (sometimes higher to compensate for low bioavailability)
Higher doses (up to 50 mg/day) have been trialled without clear additional benefit over 5–10 mg

Timing:

Typically dosed in the evening, aligning with pineal function
Some protocols use morning dosing; community consensus leans evening

Cycle:

Standard: 10–20 consecutive days, once or twice per year
Not recommended for continuous long-term use — cycling is important, partly because effects persist well after discontinuation (weeks of circadian/melatonin benefit from a 14-day cycle)
Some aggressive protocols run 2–3 cycles per year; Khavinson’s own research typically used annual or semi-annual cycling

Stacking:

Often stacked with other “longevity peptides” — MOTS-c, Thymalin, Thymosin Alpha-1
Compatible with most biohacker stacks; no known significant interactions
DSIP and Epithalon are sometimes combined for sleep-focused use, though mechanisms overlap
Not typically combined with GLP-1s (no interaction documented, but different use-cases)

For sensitive systems

Epithalon has a relatively benign profile for sensitive populations compared to BPC-157 or Semax — it’s not a known mast cell trigger, not strongly sympathetic-activating, and the circadian/sleep effects may genuinely benefit HPA-axis-dysregulated users. However, the cancer concern (see Areas of concern) requires its own consideration.

Start dose. For sensitive users running injection: 2–3 mg/day for 5–7 days, then increase to 5 mg if tolerated. For intranasal: 1–2 mg/day.

Ramp. Epithalon is cycled, not ramped. Complete a shorter initial cycle (7–10 days) at lower dose before committing to the standard 10–20 day protocol.

Expected adjustment profile:

Sleep changes are the main signal. Users typically report deeper sleep within 3–5 days; this is usually welcome but can be disruptive if it coincides with unusually vivid dreams or night-time awakening patterns.
Injection site irritation — mild, short-lived, localised. Minimal for intranasal.
Circadian shift — some users report their natural wake time shifting earlier during a cycle. Not unwelcome but worth tracking.
Mood changes — occasional reports of mood shifts (positive or subtle flatness) during cycles, consistent with melatonin-system changes
No documented histamine/mast cell provocation — unlike BPC-157, Epithalon is not a known mast cell trigger. Theoretically safer for MCAS users than many peptides.

What’s not normal and warrants stopping: severe insomnia (paradoxical), significant mood changes, any new symptom suggesting endocrine disruption.

Why Epithalon may be useful for sensitive systems:

Melatonin restoration is directly relevant to MCAS, UARS, POTS, long COVID populations — melatonin has anti-inflammatory effects, regulates mast cell activity, and is often disrupted in these conditions
Circadian rhythm repair is foundational for HPA-axis healing, and Epithalon is one of few interventions with mechanism-specific circadian effects
Low histamine-provocation risk relative to most peptides
Cortisol rhythm normalisation (documented in primates) is mechanistically relevant to cortisol dysregulation in chronic illness populations

What to have on hand:

A way to track sleep metrics (Oura, Apple Watch, Whoop) — Epithalon’s most measurable effect is on sleep architecture
A way to track wake time if circadian shifting happens

Interactions worth considering:

Melatonin supplementation: no documented interaction, but mechanistic overlap is obvious. Many users take both during cycles; some prefer to pause melatonin and let Epithalon restore endogenous production. Not well studied either way.
SSRIs/SNRIs: no documented interaction
LDN: no documented interaction
Hormone replacement therapy: Epithalamin (the related compound) is approved in Russia for menopause symptoms — suggesting Epithalon may interact with reproductive hormones in ways not well characterised. Worth additional caution in users on HRT.
Immunosuppressants or biologics: mechanistic overlap through IL-2 and thymocyte effects; not a known clinical issue but worth flagging.

PMDD note: Epithalon’s circadian and cortisol-rhythm effects may be relevant to PMDD (which has documented circadian and HPA-axis components). The related compound Epithalamin is Russian-approved for menopause-related symptoms. Mechanistically plausible benefit, with no specific PMDD research yet.

Reasonable expectations

Onset. Sleep effects typically reported within 3–5 days of starting a cycle. Circadian effects emerge across 7–14 days. Telomere/longevity effects are not perceivable subjectively and cannot be claimed from short cycles — these are markers measured in blood tests or inferred from long-term follow-up.

Response rate. Sleep improvement is reported by most users (~70–80% subjective benefit). Other effects (energy, cognition, general well-being) are more variable.

What the literature actually supports.

Telomere length extension in cell lines: now supported by one Khavinson-group and one independent 2025 replication. Legitimate mechanism.
Melatonin restoration in aged primates: consistent signal
Modest lifespan extension in rodents: Khavinson group data; not independently replicated in long-lived species
Circadian rhythm effects: reasonably supported in aged primates
Human lifespan or healthspan benefit: not demonstrated. The human studies are on biomarkers (telomere length, sleep quality, biomarkers of ageing), not on hard clinical endpoints like mortality, cardiovascular events, or cancer incidence.

What not to expect.

Measurable reversal of ageing. Telomere extension in blood cells is a biomarker, not a clinical outcome.
Protection against all cancers — and see Areas of concern for the specific case where it may do the opposite.
Dramatic subjective rejuvenation effects. Most users describe subtle sleep and recovery improvements, not transformation.
Replacement for HRT, sleep medications, or comprehensive longevity protocols
Evidence comparable to rapamycin, metformin, or exercise for longevity. Epithalon’s evidence base is meaningfully weaker.

Cost

Approximate as of April 2026, research-chemical market, UK-focused. Vendor-neutral.


10 mg lyophilised vial (injectable)	£20–45
50 mg vial (bulk)	£60–120
0.1% nasal spray / drops	£30–55
Cost per 14-day cycle, community-standard (7 mg/day injection)	~£40–80
Cost per 14-day cycle, sensitive-start (3 mg/day injection)	~£20–35
Cost per year, 2 cycles at standard dose	~£80–160

Epithalon is one of the most cost-effective peptides to run because protocols are short cycles rather than continuous use. Annual cost is meaningfully lower than daily-use compounds.

Reconstitution

10 mg lyophilised Epithalon:

Reconstitute in 2 mL bacteriostatic water → 5 mg/mL
5 mg dose = 1 mL = 100 IU on a U-100 insulin syringe (a full insulin syringe)
10 mg dose = 2 mL (usually split across two injections or use a larger reconstitution volume)

Alternative: 10 mg in 5 mL BAC water → 2 mg/mL

5 mg dose = 2.5 mL (larger volume injection)
Allows more precise dosing for sub-5 mg doses

Nasal spray (0.1%):

A 100 µL spray delivers ~100 mcg
For 2 mg (2,000 mcg) intranasal dose: 20 sprays across the day — often split morning and evening, or taken across 10 sprays per nostril session

Open the Vial Plan calculator

Reconstituted Epithalon is stable in BAC water, refrigerated, for ~30 days. Freezing is debated; most sources recommend against freezing once reconstituted. Lyophilised Epithalon is stable at room temperature for months.

Areas of concern ⚠

The cancer concern requires specific attention

This is the most important section of this document.

The mechanism:

Telomerase activation is the central mechanism by which most cancer cells achieve replicative immortality. Epithalon activates telomerase in normal cells — that’s the desired effect for longevity purposes.
The 2025 Brunel University study tested Epithalon in breast cancer cell lines and found that while normal cells show large increases in telomerase activity, cancer cells instead showed a ten-fold increase in ALT (Alternative Lengthening of Telomeres) activity — another immortalisation mechanism cancers use.1
In other words: Epithalon may provide cancer cells with telomere-extending mechanisms through at least two pathways.

The counter-evidence:

Khavinson-group animal studies have repeatedly shown reduced spontaneous tumour incidence and reduced metastasis in tumour-prone mouse strains treated with Epithalon.
Proposed oncostatic and anti-metastatic effects have been described.
The in vitro 2D cell-culture model is not equivalent to human tumour behaviour — authors of the 2025 study acknowledge this explicitly.

What this means in practice:

In someone with no cancer history: the rodent oncostatic data is reassuring but not definitive. The in vitro ALT finding is concerning but not clinically established.
In someone with active cancer or recent cancer history: this compound is not appropriate. The theoretical mechanism for tumour growth acceleration is real and cannot be dismissed.
In someone with strong family history of cancer: serious personal decision. The decision should not rest on biohacker content. A personalised discussion with an oncologist who understands both telomerase biology and the specific family cancer pattern is the right move.
Screening should be current before starting an Epithalon cycle — routine cancer screening appropriate for age, sex, family history, and personal risk factors.

This is one of the clearest cases in this reference set where a theoretical risk materially affects the bottom line: if you have active cancer or a significant cancer history, this is not an appropriate compound to use, even though it is legally available as a research chemical.

Other safety concerns

Half-life is not established. You don’t know how long the compound persists in circulation. This matters for dosing intervals and for assessing real drug exposure.
Long-term human data is limited. Most human studies are small, short, and from one research group.
Independent replication is recent and limited. The 2025 Brunel paper is the first meaningful Western academic engagement with this compound in 40 years of its existence. Ongoing watch is warranted.

Evidence-base concerns

Khavinson-group monopoly problem. Until 2025, essentially all Epithalon research came from one Russian group. This is not inherently wrong — some compounds are studied mostly by their discoverers — but it means the evidence is one-perspective by default.
Epithalamin vs Epithalon conflation. Russian regulatory approval is for Epithalamin (bovine pineal extract), not synthetic Epithalon. Content that cites “Russian approval” for Epithalon is often misrepresenting the facts.

Route-specific issues

Intranasal underdosing. 5–15% bioavailability vs injection means standard intranasal doses likely do not replicate the systemic effects documented in injection studies. Users relying on intranasal for longevity effects may be under-medicating.
Preservative sensitivity in commercial nasal sprays

Quality and sourcing

Research-chemical Epithalon is widely available and relatively cheap. Purity varies.
A 2025 supply-chain note: increased demand following longevity-space growth has led to more aggressive marketing by research-chemical suppliers; independent purity verification is rare
Storage: lyophilised is stable at room temp; reconstituted solution refrigerated and used within 30 days

Populations where caution is warranted

Active or recent malignancy — treat as contraindicated, not just cautionary
Strong personal or family history of cancer — serious personalised decision; not appropriate for generic biohacker use
Pregnancy and breastfeeding — no data, default contraindication
Hormone-dependent conditions (certain breast and prostate cancers, endometriosis, hormone-related infertility) — mechanism overlap with Epithalamin’s Russian indications raises questions
Under 18 — no data

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Not approved. Not on 503A Category 1 or Category 2 lists. Not covered by the February 2026 reclassification announcements.	2026-04-24
UK (MHRA)	Not licensed. Not a controlled substance. Sold as research chemical with “not for human consumption” labelling.	2026-04-24
EU (EMA)	Not approved. Similar posture to UK.	2026-04-24
Russia	Not approved as a medicine. Epithalamin (bovine pineal extract) is approved in Russia; Epithalon (synthetic AEDG tetrapeptide) is not.	2026-04-24
WADA (sport)	Not explicitly listed. Treat as prohibited for tested athletes under general peptide/hormone category.	2026-04-24

Narrative. Epithalon is globally unapproved despite 40+ years of Russian research. Its parent compound Epithalamin is approved in Russia for specific indications; the synthetic tetrapeptide is not. Most claims of “Russian approval” for Epithalon conflate the two. The compound is legally available as a research chemical in the UK, US, and EU.

For UK readers: Epithalon is legally available as a research chemical from UK-based suppliers. Not a controlled substance. Personal possession is not an offence. Sale for human consumption is not permitted.

What to track in Peptrax

Epithalon is the hardest compound on this list to evaluate honestly, because the headline claim — telomere lengthening, slowed biological aging — is not something you can feel on a weekly timescale. The reasonable thing to track is what’s actually possible to track: sleep quality across the cycle, subjective recovery, and any week-to-week changes in resilience or energy floor. Pretending you can sense telomerase activity is the easy mistake; logging what you genuinely notice is more useful.

Cycle structure is unusually distinctive. Standard protocols are 10–20 day cycles followed by months of off-time, often once or twice per year. The relevant Peptrax fields are cycle start and end dates, dose per day, route (subQ dominant; intranasal exists), and a brief weekly reflection during and after each cycle. The off-period observations matter as much as the on-period — if anything changed, it changed because of the cycle but is being measured later.

For users running this for the longevity thesis specifically, the only honest biomarker is testing — basic bloods, ideally a biological-age clock if affordable — bookending the cycle. The app cannot run those tests, but it can hold the dates, results, and your reflection on whether the biomarker movement matched the subjective experience. The risk Epithalon shares with all longevity compounds is spending money for years on something whose effect is invisible without measurement; tracking is what makes that conversation honest.

For personal tracking and informational purposes only — not medical advice.